Jagsonpal Pharmaceuticals Limited — Investor Meet, 29-10-2024: Analysts/Institutional Investor Meet/Con. Call Updates

Jagsonpal Pharmaceuticals Limited recently hosted its Q2 and H1 FY25 earnings call, reporting a 29% revenue growth to ₹75 crores. The company emphasized its commitment to gynaecology and orthopaedics, highlighting the positive recovery in key products. Key initiatives include the “MySakhi” CSR program aimed at advancing women’s health and a stock split to enhance share liquidity. Future growth may stem from new product launches and potential acquisitions, with a focus on operational efficiency and margin improvement.